Alternative strategies for vaccine development against avian flu

Michele A. Zacks, Slobodan Paessler

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Intense focus has been placed on investigation of vaccine strategies that provide cross-protection against H5N1. In April of 2007, an inactivated influenza A/Vietnam/ 1203/04 (H5N1) vaccine developed by Sanofi-Aventi was approved by the U.S. Food and Drug Administration, despite its suboptimal efficacy profile. Nonetheless, other approaches to vaccine development are being tested, including recombinant subunit, viral vectored and plasmid DNA (pDNA) vaccines. This chapter will focus on several alternative H5N1 vaccines and therapeutic antibody approaches not covered in previous reviews: linear DNA vaccines, protein-based flagellin conjugate vaccines, and an alphavirus based vaccine approach. In addition, we describe some of the animal models potentially useful for testing the efficacy of the vaccine candidates against avian influenza.

Original languageEnglish (US)
Title of host publicationGlobal View of the Fight Against Influenza
PublisherNova Science Publishers, Inc.
Pages199-208
Number of pages10
ISBN (Print)9781607419525
StatePublished - Jul 2009

Fingerprint

Influenza in Birds
contagious disease
Vaccines
Vietnam
DNA Vaccines
candidacy
animal
Cross Protection
Alphavirus
Flagellin
Conjugate Vaccines
United States Food and Drug Administration
Human Influenza
Plasmids
Animal Models
Antibodies
Proteins

ASJC Scopus subject areas

  • Medicine(all)
  • Social Sciences(all)

Cite this

Zacks, M. A., & Paessler, S. (2009). Alternative strategies for vaccine development against avian flu. In Global View of the Fight Against Influenza (pp. 199-208). Nova Science Publishers, Inc..

Alternative strategies for vaccine development against avian flu. / Zacks, Michele A.; Paessler, Slobodan.

Global View of the Fight Against Influenza. Nova Science Publishers, Inc., 2009. p. 199-208.

Research output: Chapter in Book/Report/Conference proceedingChapter

Zacks, MA & Paessler, S 2009, Alternative strategies for vaccine development against avian flu. in Global View of the Fight Against Influenza. Nova Science Publishers, Inc., pp. 199-208.
Zacks MA, Paessler S. Alternative strategies for vaccine development against avian flu. In Global View of the Fight Against Influenza. Nova Science Publishers, Inc. 2009. p. 199-208
Zacks, Michele A. ; Paessler, Slobodan. / Alternative strategies for vaccine development against avian flu. Global View of the Fight Against Influenza. Nova Science Publishers, Inc., 2009. pp. 199-208
@inbook{83f9a86f1b1645beaeea36e8611801ba,
title = "Alternative strategies for vaccine development against avian flu",
abstract = "Intense focus has been placed on investigation of vaccine strategies that provide cross-protection against H5N1. In April of 2007, an inactivated influenza A/Vietnam/ 1203/04 (H5N1) vaccine developed by Sanofi-Aventi was approved by the U.S. Food and Drug Administration, despite its suboptimal efficacy profile. Nonetheless, other approaches to vaccine development are being tested, including recombinant subunit, viral vectored and plasmid DNA (pDNA) vaccines. This chapter will focus on several alternative H5N1 vaccines and therapeutic antibody approaches not covered in previous reviews: linear DNA vaccines, protein-based flagellin conjugate vaccines, and an alphavirus based vaccine approach. In addition, we describe some of the animal models potentially useful for testing the efficacy of the vaccine candidates against avian influenza.",
author = "Zacks, {Michele A.} and Slobodan Paessler",
year = "2009",
month = "7",
language = "English (US)",
isbn = "9781607419525",
pages = "199--208",
booktitle = "Global View of the Fight Against Influenza",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Alternative strategies for vaccine development against avian flu

AU - Zacks, Michele A.

AU - Paessler, Slobodan

PY - 2009/7

Y1 - 2009/7

N2 - Intense focus has been placed on investigation of vaccine strategies that provide cross-protection against H5N1. In April of 2007, an inactivated influenza A/Vietnam/ 1203/04 (H5N1) vaccine developed by Sanofi-Aventi was approved by the U.S. Food and Drug Administration, despite its suboptimal efficacy profile. Nonetheless, other approaches to vaccine development are being tested, including recombinant subunit, viral vectored and plasmid DNA (pDNA) vaccines. This chapter will focus on several alternative H5N1 vaccines and therapeutic antibody approaches not covered in previous reviews: linear DNA vaccines, protein-based flagellin conjugate vaccines, and an alphavirus based vaccine approach. In addition, we describe some of the animal models potentially useful for testing the efficacy of the vaccine candidates against avian influenza.

AB - Intense focus has been placed on investigation of vaccine strategies that provide cross-protection against H5N1. In April of 2007, an inactivated influenza A/Vietnam/ 1203/04 (H5N1) vaccine developed by Sanofi-Aventi was approved by the U.S. Food and Drug Administration, despite its suboptimal efficacy profile. Nonetheless, other approaches to vaccine development are being tested, including recombinant subunit, viral vectored and plasmid DNA (pDNA) vaccines. This chapter will focus on several alternative H5N1 vaccines and therapeutic antibody approaches not covered in previous reviews: linear DNA vaccines, protein-based flagellin conjugate vaccines, and an alphavirus based vaccine approach. In addition, we describe some of the animal models potentially useful for testing the efficacy of the vaccine candidates against avian influenza.

UR - http://www.scopus.com/inward/record.url?scp=84896409808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896409808&partnerID=8YFLogxK

M3 - Chapter

SN - 9781607419525

SP - 199

EP - 208

BT - Global View of the Fight Against Influenza

PB - Nova Science Publishers, Inc.

ER -